Dianthus Therapeutics Inc. has filed a final prospectus supplement with the U.S. Securities and Exchange Commission detailing the terms of its latest public offering. The company plans to issue and sell 6,487,879 shares of its common stock at a public offering price of $33.00 per share. Additionally, Dianthus will offer pre-funded warrants to purchase 1,112,121 shares of common stock at a price of $32.999 per warrant, which takes into account a $0.001 per share exercise price. The net proceeds from the offering, expected to be approximately $270 million, will be used after deducting underwriters' discounts, commissions, and estimated offering expenses. The offering is set to close on September 11, 2025, following the full exercise of an option by the underwriters to purchase an additional 1,140,000 shares.